Blog barnaclínic


  1. 29 April, 2022

    barnaclínic+ launches its Dermatological Diagnosis Unit

    Diagnóstico cáncer de piel y melanoma

    Skin cancer is the most frequent tumour and it is estimated that 20% of people will develop it throughout their lives. In Spain alone, this disease affects 300 people out of 100.000 each year. Malignant melanoma, on the other hand, is a tumour that is caused by an abnormal growth of some skin cells, whose incidence in recent years is possibly increasing in relation to sun exposure habits. Because these skin tumours appear externally, they are easier to detect and if they are diagnosed in the early stages, they have a high chance of cure. Due to this importance of early diagnosis, barnaclínic+ has launched its Dermatological Diagnosis Unit.

    Read more…

  2. 22 March, 2022

    Hospital Clínic, one more year among the best hospitals in the world in the World’s Best Hospitals

    Mejores hospitales del mundo

    For another year, Newsweek magazine, in collaboration with Statista, has produced its ranking of the best hospitals in the world, the World’s Best Hospitals, thus being the fourth time that this classification has been awarded. And for yet another year, the Hospital Clínic has been among the best hospitals in the world and in Spain. On this occasion the centre has occupied the second position of the Spanish top 3, only behind the Hospital Universitario La Paz, while the Hospital Universitario 12 de Octubre completed the podium in third position. Regarding the world ranking, the Hospital Clínic has occupied the 63rd position. Read more…

  3. 18 March, 2022

    A pioneering surgical technique in Europe allows reversing male infertility

    Male infertility can be caused by multiple causes, among which there may be physical problems. In some cases, it is possible to solve these problems through surgery. The Urology Department of the Hospital Clínic Group, directed by Dr Antonio Alcaraz, is now a pioneer in Europe in carrying out a new surgical technique that allows for much more accurate procedures in these interventions and thus achieves a better recovery for the patient: the Micro Thesis or microsurgical retrieval of sperm assisted with the Olympus Orbeye exoscope.

    Read more…

  4. 4 March, 2022

    The Clinic is a pioneer in Spain in the extraction of tumours from the base of the skull through the eye

    In recent years, surgery has developed enormously to achieve increasingly less invasive interventions. Achieving the same results as traditional open surgeries, these new approaches achieve a faster recovery for patients and minimize the risks of operations, which is why their use is becoming more and more widespread. Now, the Hospital Clínic Group has begun to perform surgeries through the eye to remove tumours from the base of the skull, becoming the first centre in Spain to perform transorbital neuroendoscopic surgery and one of the few in the rest of the world to use it.

    Read more…

  5. 2 March, 2022

    Visiõnclínic+ is born in order to offer excellent personalised ophthalmological care

    visiõnclínic+ - Oftalmología barnaclínic+

    Visual health is the key to people’s quality of life. In order to detect possible visual problems in the earliest stages and find the most appropriate treatment for each person, it’s vital to offer the most personalised care possible. Precisely, to focus on the patients, the team of world-renowned ophthalmological professionals at Hospital Clínic Group, led by Dr. Alfredo Adán, was set up by visiõnclínic+. A unique project that features the most advanced technological equipment and modern facilities distributed among the Maternity headquarters and a few new surgeries located in Vía Augusta on the Mi Tres Torres Campus.

    Read more…

  6. 18 February, 2022

    The CAR-T ARI-0001 developed by the Hospital Clínic obtains the PRIME designation from the European Medicines Agency

    ARI-0001 is a CAR-T therapy that has been developed at Hospital Clínic for the treatment of acute lymphoblastic leukaemia. In February 2021, the Spanish Agency for Medicines and Health Products (AEMPS) approved its use and it became the first treatment with genetically modified cells and fully developed in Europe that was approved by a regulatory agency. The path of ARI-0001 has not stopped here, and now the European Medicines Agency (EMA) has granted it the PRIME designation, which means that it has become a priority for the agency thus offering its support for an evaluation acceleration of this therapy.

    Read more…

  7. 28 January, 2022

    A new genomic test allows personalising the treatment of HER2+ breast cancer

    Cancer is a very heterogeneous disease and that is why research is being carried out to develop treatments that are adapted to the characteristics of each subtype. But then there is the challenge of identifying which patients benefit most from each treatment. With this in mind, HER2DX has been created, a genomic test that predicts survival and the possibility of responding to treatment in HER2-positive breast cancer patients in their earliest stages. This tool is the first genomic test created worldwide for this disease and researchers from the Clínic – IDIBAPS – UB, the Vall d’Hebron Instituto de Oncología, the Università di Padova (Italia) and REVEAL GENOMICS.

    Read more…

  8. 27 December, 2021

    Liquid biopsy shows its utility in the analysis of cancer

    Biopsia líquida

    One of the big challenges in the treatment of cancer is its heterogeneity. Tumours can present different mutations and change with time, which means that not all treatments are effective or they generate resistance. That’s why it is important to carry out follow-ups that allow us to identify changes as they are produced. However, getting the precise samples to carry out this analysis via a tissue biopsy isn’t always easy. That’s why, in the last few years, a new method has been developed which allows to analyse tumoural DNA circulating in the blood in order to carry out this follow-up and analysis of cancer in an easy and simple way. This is known as liquid biopsy.

    Read more…

  9. 23 December, 2021

    The Hospital Clínic Group develops a second CAR-T, suitable for multiple myeloma resistant to treatment

    CAR-T para el Mieloma múltiple

    The Hospital Clínic Group of Barcelona along with the August Pi and Sunyer Biomedical Research Institute (IDIBAPS) have developed a new CAR-T, the ARI-0002h, for patients with multiple myeloma resistant to habitual treatments. The results of a clinical trial, recently presented in the American Society of Hematology (ASH), which was held in Atlanta, have demonstrated that this new CAR-T for multiple myeloma is capable of getting a response rate of up to 75% after a year of treatment and that in 60% of patients that have complete remission and without residual disease, results that are, without doubt, very hopeful.

    Read more…

  10. 30 November, 2021

    Stanford University places 18 professionals from barnaclínic+ among the most influential scientists in the world

    científicos más influyentes del mundo

    How can you evaluate the quality of a researcher’s work? One of the criteria that is most taken into account for this is to evaluate the number of times that other researchers cite them in their articles. Based on this criteria, Stanford University, in the U.S., this last 19th of October published the “World Ranking of Top 2% Scientists”. This list identifies the most influential researchers in the world, whose works have been most cited during their scientific career evaluated between 1996 and 2020 and also during the last year.

    Read more…